In the news

Endogenex™ Announces First Patient Enrolled in the ReCET Clinical Study

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes

Endogenex™ Receives IDE Approval to Initiate Pivotal Clinical Study

Stacey Pugh Combines Bedside Background with Market Experience to Affect Change for Type 2 Diabetes

Endogenex™ Appoints Christopher Sorli as Chief Medical Officer

Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive Officer